The FDA’s revocation of chloroquine and hydrochloroquine’s Emergency Use Authorization (EUA) after three months could mean the FDA may raise the bar for Covid-19 vaccines, requiring early protection data. Vaccines are sensitive to public scrutiny, specifically with limited data. However, the EUA is also sensitive to political pressure, even if it is designed to be evidence-based.
Nevertheless, manufacturing capabilities could also be a deciding criterion. This added factor could impact vaccines based on new technologies or developers with less production experience. Read more here.